Catalyst for next move up I am guessing that the company will announce the efficacy from their P2/3 clinical study when they submit their FDA approval request. This would generate some investor interest and, since the efficacy results are expected to be spectacular, it would likely kick the stock price much higher. They could then issue some shares and pay off the debt, cutting their breakeven point because they would get rid of the interest expense.
But, these little companies keep breaking my heart. Maybe they will take the Endo approach and say almost nothing until after FDA approval, to avoid irritating the FDA.
What are your thoughts?